Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 600x60px
Document › Details

Epigenomics AG. (11/14/16). "Press Release: Epigenomics AG to Participate in Investor Conferences". Berlin & Germantown, MD.

Organisations Organisation Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY)
  Group Epigenomics (Group)
  Organisation 2 Canaccord Genuity Corporation
  Group Canaccord Genuity (Group)
Products Product Epi proColon® blood test
  Product 2 Deutsches Eigenkapitalforum 2016 Frankfurt (German Equity Forum 2016)
Index term Index term Epigenomics–Deutsche Börse: investor conference, 201611 supply service Epigenomics AG presents at Deutsches Eigenkapitalforum 2016
Persons Person Hamilton, Gregory (Greg) (Epigenomics 201607– CEO before AltheaDx + Enigma Diagnostics + Third Wave + Hologic)
  Person 2 Vogt, Peter (Epigenomics 201601 Investor + Public Relations)

Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY) today announced that Greg Hamilton, Chief Executive Officer, will participate in the following investor conferences:

> Canaccord Genuity Medical Technologies & Diagnostics Forum, Thursday November 17, 2016, New York, Westin New York Grand Central, Presentation: 10:00 am (EST)

> German Equity Forum 2016, Tuesday, November 22, 2016, Frankfurt, Sheraton Frankfurt Airport Hotel, Presentation: 5:00 PM (CET)

> goetzpartners Interdisciplinary Oncology Insight Symposium, November 29, 2016, London, Le Meridien Piccadilly, Panel discussion: 2:00 PM (GMT)

About Epigenomics

Epigenomics is a molecular diagnostics company focused on blood-based detection of cancers using its proprietary DNA methylation biomarker technology. The company develops and commercializes diagnostic products across multiple cancer indications with high medical need. Epigenomics' lead product, Epi proColon, is a blood-based screening test for the detection of colorectal cancer. Epi proColon has received approval from the U.S. Food and Drug Administration (FDA) and is currently marketed in the United States, Europe, China and selected other countries. Epigenomics’ second product, Epi proLung®, is in development as a blood-based test for lung cancer detection.

For more information, visit

Contact Epigenomics AG
Peter Vogt
Vice President Corporate Communications & Investor Relations
Epigenomics AG
Geneststraße 5
10829 Berlin
Phone +49 (0) 30 24345 386

Record changed: 2017-07-02


Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 273x168px

More documents for Epigenomics (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [LSUS] – The Business Web Portal 600x60px

» top